The world health organization said earlier in the day that it has granted prior qualification to tocilizumab, which is treated for arthritis, for use in patients admitted to corona hospitals. The monoclonal antibody, created by Swiss pharma giant Roche, helps in reducing the risk of death in people with corona and spending less time in hospital. The World Health Organization has already recommended its use for the treatment of severe corona patients in hospitals like the European Union, including the United States. 

According to the news received, it is in small quantities and very expensive. In low-income countries, a single dose of it goes up to $600. The World Health Organization said its pre-qualification could help make it more available. Tocilizumab was previously used mostly for the treatment of arthritis in 120 countries. At the same time, at the time of the epidemic, it has been seen to be helpful in suppressing a frightening cytokine storm. 

The World Health Organization discussed with Roche on Tocilizumab and discussed how to bring its prices to low and low-income countries. At the same time, AFP now insists that the prequalification was for Roche products. Many generic companies are already producing Tocilizumab and many of them had applied for prequalification. At the same time, if they comply with the World Health Organization's standard, they will be able to enter international markets.

IPL Mega Auction: From today, players will be showered with money

The danger of corona is not averted! WHO has warned

Internet in rural India growing fast, soon surpass urban connectivity: FM